Transgene is designing and developing next-generation immunotherapeutics against cancer
TG4050
One patient, one cancer, one vaccine
TG4050 is an individualized neoantigen cancer vaccines from Transgene’s myvac® platform, based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities. TG4050 is being evaluated in a Phase I/II clinical trial.
TG4050 video
Watch Alessandro Riva presenting first clinical benefits of neoantigen cancer vaccine, TG4050, in head & neck cancer at AACR 2024
Innovative technologies
Push the boundaries of immunotherapy
Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.
Discover our myvac® platform
Discover our invir.IO® platform
Oncolytic viruses
A new generation of products
These innovative multifunctional OVs, from Transgene’s invir.IO® platform, are able to modulate the tumor microenvironment to better attack cancer.
Oncolytic viruses video
Three therapeutic approaches
Transgene’s immunotherapies harness the mechanisms of the immune response to enable the patient’s body to fight against disease.
- SITC
SITC 2024
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
Donwload Press release (PDF)
Donwload the Poster (PDF) - Presentation
Transgene in a nutshell
Corporate Presentation
Universal Registration Document
Press releases
Last publications
- November 7, 2024 - Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)
- October 27, 2024 - TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery
- October 7, 2024 - Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024